In line with previous findings (45, 62–65), we were able to confirm that CD8+ and CD4+ T cell responses to SARS-CoV-2 are retained in MS patients under anti-CD20 depletion therapy, i.e., when comparing time points t0 vs. t1, where t0 and t1 correspond to before and after the first dose ocrelizumab. Here, CD8A is linked to myeloid sarcoma.